SPOTLIGHT: Once-daily Seroquel OK'd

AstraZeneca won FDA approval for a new, once-daily version of Seroquel, significantly extending the product life of a drug that earned $3.4 billion last year. The schizophrenia drug is AstraZeneca's second biggest seller. The new version will be under patent until 2017. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.